Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Does Clovis Oncology Inc (CLVS) Represent a Good Addition to Your Portfolio?

Page 1 of 2

The elite funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary to beat the market. That’s why we pay close attention to what they think in small cap stocks. In this article, we take a closer look at Clovis Oncology Inc (NASDAQ:CLVS) from the perspective of those elite funds.

Is Clovis Oncology Inc (NASDAQ:CLVS) a good investment right now? Investors who are in the know seem to be in a bullish mood, as the number of funds tracked by Insider Monkey long the stock advanced by 12 to 33 between July and September. At the end of this article we will also compare CLVS to other stocks including Heritage Financial Corporation (NASDAQ:HFWA), Rapid7 Inc (NASDAQ:RPD), and Lands’ End, Inc. (NASDAQ:LE) to get a better sense of its popularity.

Follow Clovis Oncology Inc. (NASDAQ:CLVS)
Trade (NASDAQ:CLVS) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

pharmacist, worker, shelves, business, counter, glasses, attractive, medical, competence, chemist, adult, clinic, drugstore, selling, female, consultation, medicine, coat

racorn/Shutterstock.com

Keeping this in mind, we’re going to go over the fresh action surrounding Clovis Oncology Inc (NASDAQ:CLVS).

What have hedge funds been doing with Clovis Oncology Inc (NASDAQ:CLVS)?

As stated earlier, a total of 33 funds tracked by Insider Monkey were long Clovis Oncology at the end of September, a change of 57% from one quarter earlier. With hedge funds’ capital changing hands, there exists a few key hedge fund managers who were boosting their stakes meaningfully (or already accumulated large positions).
1
When looking at the institutional investors followed by Insider Monkey, Palo Alto Investors, managed by William Leland Edwards, holds the biggest investment in Clovis Oncology Inc (NASDAQ:CLVS). Palo Alto Investors has a $137.1 million position in the stock, comprising 8% of its 13F portfolio. The second largest stake is held by Mitchell Blutt’s Consonance Capital Management, which disclosed a $127.3 million position; the fund has 12.3% of its 13F portfolio invested in the stock. Other professional money managers that hold long positions consist of Zach Schreiber’s Point State Capital, Jeremy Green’s Redmile Group, and Dmitry Balyasny’s Balyasny Asset Management.

Page 1 of 2
Loading Comments...